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 Abstract 
A loss of skeletal muscle function and mass is a hallmark of several diseases 
resulting in a dismal life quality and poor prognosis. Impaired intracellular Ca2+-
handling has been proposed as an underlying cause of these manifestations. This 
thesis investigated the cellular mechanisms of human muscle fatigue and disease-
related loss of muscle function and mass. Special focus was put on the 
contribution of altered intracellular Ca2+-handling to these processes. The thesis 
makes three main contributions by: (i) providing mechanistic insight into the 
underlying causes of fatigue in human muscle fibres, (ii) elucidating the direct 
effects of vitamin D in human muscle, and (iii) implicating sphingomyelinase 
(SMase) activation in disease-related loss of muscle function and mass. 
Study I examined single intact muscle fibres and differentiated muscle stem 
cells (myotubes) as experimental models of human skeletal muscle. Results 
revealed that single intact fibres could be manually dissected, enabling studies of 
Ca2+-regulated processes and force generation. Major differences in intracellular 
Ca2+-handling between myotubes and muscle fibres were discerned. In study II, 
the effects of vitamin D in human skeletal muscle were investigated. Data 
demonstrated a modulatory role of vitamin D on muscle stem cells, but did not 
support presence of the vitamin D receptor in muscle fibres. In study III, the 
cellular mechanisms of fatigue were examined in single intact fibres. Fatigue-
induced force loss was caused by a reduction in sarcoplasmic reticulum (SR) Ca2+ 
release, while a decrease in myofibrillar Ca2+ sensitivity played no role. 
Acidification did not reduce force production or fatigue tolerance of human 
fibres. Study IV investigated the tentative role of SMase in disease-related 
muscle weakness and atrophy. SMase produced a prompt force decline by a 
reduction in SR Ca2+ release and decreased myofibrillar Ca2+ sensitivity, while 
promoting atrophy processes. Intramuscular SMase activity was elevated in heart 
failure compared to control individuals, and positively correlated with circulating 
markers of inflammation and atrophy, and with factors carrying prognostic value.  
This thesis reveals differences in the intracellular Ca2+-handling properties of 
myotubes and muscle fibres, and in the underlying causes of fatigue in humans 
and animals. This warrants caution when transferring findings in animal fibres 
and human myotubes to the situation in human skeletal muscle.  The effects of 
vitamin D on muscle stem cells suggest an importance of vitamin D in skeletal 
muscle health. This should be considered in conditions of severe vitamin D 
deficiency, e.g. chronic kidney disease. Results implicate elevated SMase 
activity in the advent of muscle weakness and atrophy, suggesting SMase as a 
tentative target for therapeutic interventions in diseases associated with a loss of 
skeletal muscle function and mass.   
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1 Introduction and background 
Several human diseases are associated with a high incidence of a profound and 
debilitating loss of skeletal muscle function and mass that result in a dismal life 
quality and poor prognosis (Anker et al., 1997; Hulsmann et al., 2004; Sokka et 
al., 2008; Chung et al., 2014; Powers et al., 2016). More than just the result of 
muscle disuse, disease-related changes inside the skeletal muscle fibres contribute 
to the progressive skeletal muscle dysfunction (Ward et al., 2003; Powers et al., 
2016; Steinz et al., 2019). Experimental evidence from animal models has 
implicated dysfunctional intracellular Ca2+-handling with the impaired muscle 
function (Reiken et al., 2003; Ward et al., 2003; Yamada et al., 2015b; Llano-
Diez et al., 2016). Factors suggested to contribute to the changes in intracellular 
Ca2+-handling include increased neuroendocrine activation, elevated circulating 
levels of pro-inflammatory cytokines, and altered sphingolipid metabolism 
(Reiken et al., 2003; Andersson & Marks, 2010; Nikolova-Karakashian & Reid, 
2011; Reid & Moylan, 2011; Stasko et al., 2013). Meanwhile, vitamin D 
deficiency is a common finding in diseased individuals associated with muscle 
weakness and atrophy, ostensibly via both Ca2+-dependent and Ca2+-independent 
processes (Girgis et al., 2013). The current thesis investigated the intracellular 
mechanisms of human muscle fatigue and disease-related loss of muscle 
function and mass. A special focus was put on the role of altered intracellular 
Ca2+-handling in these processes. 
Skeletal muscle force development 
Skeletal muscle contraction occurs when the contractile proteins myosin and actin 
in the force generating units, the sarcomeres, interact to form cycling cross 
bridges. In this reaction, ATP serves as an energy-carrying compound while being 
converted to ADP and free organic phosphate (Pi). In the resting muscle fibre, the 
myofilament regulatory protein tropomyosin forms a complex together with 
troponin C, T and I that blocks the myosin binding-sites on actin. A 
conformational change in tropomyosin, instigated by Ca2+ binding to troponin C, 
enables myosin and actin interaction. Elevations in the myoplasmic free Ca2+ 
concentration ([Ca2+]i) promote Ca2+ binding to troponin C, while Ca2+ 
dissociation from troponin C is promoted as [Ca2+]i is lowered to its resting value 
(Gordon et al., 2000). Intracellular Ca2+ thus serves as the cellular signalling 
molecule that dictates initiation and termination of muscle contraction.  
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The level of [Ca2+]i determines the number of cross bridges that can be formed 
and thus regulates the amount of force development within individual skeletal 
muscle fibres (Gordon et al., 2000). In this way, increasing levels of [Ca2+]i results 
in larger force developments until all cross bridges are activated and the maximal 
Ca2+-activated force is produced. There is a strong correlation between muscle 
fibre diameter and potential force development (Schantz et al., 1983). Muscle 
fibre diameter is determined by the balance between protein synthesis and 
degradation, but may also be modulated by the activity of muscle stem cells, as 
will be discussed further in the following sections.  
Skeletal muscle excitation-contraction coupling  
The events from sarcolemmal depolarisation to initiation of cross bridge cycling 
are described as excitation-contraction coupling. Depolarisation of the 
sarcolemma is initiated at the neuromuscular junction when acetylcholine is 
released by the α-motoneuron (Rebbeck et al., 2014). Acetylcholine binds to 
receptors at the sarcolemma triggering the opening of ion channels that allow 
passage of both Na+ and K+. This results in a localized depolarisation of the 
sarcolemma, that when it reaches a threshold value opens voltage-gated Na+ 
channels (Nav1.4) generating an action potential that is propagated along the fibre 
via the sarcolemma and transverse tubular system (Gordon et al., 2000). In the 
transverse tubules, L-type voltage-activated Ca2+ channels (dihydropyridine 
receptor; DHPR) are activated by the propagating action potential. In skeletal 
muscle, DHPR mechanically activates the sarcoplasmic reticulum (SR) Ca2+ 
channels (type 1 ryanodine receptor; RyR1) (Tanabe et al., 1990; Rebbeck et al., 
2014). At rest, the SR lumen contains 10-20 mM Ca2+, the majority of which is 
bound to calsequestrin, while [Ca2+]i is only about 50 nM. This large 
concentration gradient allows rapid elevation of [Ca2+]i following RyR1 activation 
and opening (Allen et al., 2008).  
When α-motoneuron activation ceases the sarcolemma is repolarized, RyR1 is 
inactivated, and SR Ca2+ release stops. The re-uptake of Ca2+ into the SR by the 
SR Ca2+-ATPase (SERCA) returns [Ca2+]i to resting levels. Ca2+ dissociates from 
troponin C causing tropomyosin to again block the myosin binding-sites on actin 
whereby cross bridge cycling terminates (Gordon et al., 2000). 
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Intracellular Ca2+ in skeletal muscle physiology and 
pathology 
Intracellular Ca2+-handling refers to the cellular regulation of [Ca2+]i homeostasis, 
including the regulation of basal levels and fluctuations in [Ca2+]i, and the cellular 
response to fluctuations in [Ca2+]i. Intracellular Ca2+-handling involves a large 
number of intracellular membrane or organelle bound proteins, as well as soluble 
cytosolic or organelle-confound proteins (Berchtold et al., 2000). In skeletal 
muscle, intracellular Ca2+-handling is a key regulator and intracellular signalling 
molecule implicated in muscle force generation, fatigue development, regulation 
of gene expression and cellular metabolism (Berchtold et al., 2000; Lanner et al., 
2006; Gundersen, 2011; Tavi & Westerblad, 2011).  
Changes in [Ca2+]i transient amplitude and duration, as well as frequency of 
the [Ca2+]i transients, modulate the intracellular response to fluctuations in [Ca2+]i 
(Dolmetsch et al., 1997; Tavi & Westerblad, 2011). Based on studies in animal 
and cell models, changes in baseline [Ca2+]i have been implicated in both the 
physiological adaptation to exercise (e.g. mitochondrial biogenesis) (Bruton et al., 
2010; Place et al., 2015) and maladaptation in disease (e.g. muscle weakness, 
fatigue and atrophy) (Bhattacharyya et al., 1993; Menconi et al., 2004; Smith & 
Dodd, 2007; Dridi et al., 2020; Kushnir et al., 2020).  
Transient and prolonged changes in skeletal muscle intracellular Ca2+-handling 
may be induced by several physiological and pathological stimuli. These include 
stimuli such as acute exercise and training, muscle disuse, hormonal and 
inflammatory factors (Berchtold et al., 2000; Allen et al., 2016). Transient 
changes (seconds to hours) in intracellular Ca2+-handling are generally the result 
of changes in the levels of ions and metabolites that regulate the activity of Ca2+-
handling proteins. Prolonged changes (hours to days) may be caused by 
posttranslational modifications, changes in protein expression or stability of Ca2+-
handling proteins, or changes in the binding of regulatory proteins to Ca2+-
handling proteins (Berchtold et al., 2000; Place et al., 2015).  
Skeletal muscle fatigue 
Skeletal muscle fatigue has been defined as the reversible reduction in maximal 
voluntary force/power-producing capacity following prolonged or repeated 
contractions (Gandevia, 2001; Place et al., 2010). A distinction between central 
and peripheral components limiting force production in fatigue is often made. 
Central fatigue refers to processes within the nervous system whereas peripheral 
fatigue refers to processes at, or peripheral to, the neuromuscular junction (Taylor 
et al., 2006). It stands clear that both components participate to development of 
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fatigue, but the relative contribution of the two differs depending on the duration 
and frequency of contractions, duty cycle and external milieu (Gandevia, 2001). It 
is generally recognized that in the majority of situations a large part of fatigue 
development stems from peripheral components (Allen et al., 2008).  
Cellular mechanisms of skeletal muscle fatigue 
Studies in isolated intact and skinned mammalian muscle fibres have 
demonstrated three changes to ultimately cause the fatigue-induced force loss. 
These are (i) a reduction in myofibrillar maximal Ca2+-activated force, (ii) 
decreased myofibrillar Ca2+ sensitivity, and (iii) reduced SR Ca2+ release 
(Westerblad & Allen, 1991, 1993a; Allen et al., 2008) (Figure 1.1). The relative 
importance of these changes differs during three distinctly identifiable phases 
during fatigue; an initial phase of depressed force while tetanic [Ca2+]i increases, 
explained by a reduced myofibrillar maximal Ca2+-activated force; a second phase 
where tetanic [Ca2+]i and force is little affected; followed by a final phase in 
which both tetanic [Ca2+]i and force rapidly declines. This third phase is explained 
by a concurrent reduction in SR Ca2+ release and decreased myofibrillar Ca2+ 
sensitivity (Westerblad & Allen, 1991, 1993a; Allen et al., 2008). 
 
Figure 1.1. Illustration of the cellular mechanisms of fatigue in rodent muscle fibres. 
A, force and [Ca2+]i in the 1st, 10th and last (50th) tetanus of fatigue. Note the initial increase 
in tetanic [Ca2+]i while force decreases between the 1st and 10th tetanus. B, proposed 
sequence of events during fatigue development (red line) and mechanisms causing fatigue 
in rodent muscle fibres: (i) a reduction in myofibrillar maximal Ca2+-activated force, (ii) 
decreased myofibrillar Ca2+ sensitivity, and (iii) reduced tetanic [Ca2+]i due to impaired SR 
Ca2+ release. Force-[Ca2+]i relation in unfatigued (solid line) and fatigued (dashed line) 
fibres. Redrawn from Allen, Lamb & Westerblad; J Appl Physiol 104: 296–305, 2008. 
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Accumulation of Pi is believed to be of fundamental importance to the intrinsic 
skeletal muscle changes that ultimately causes the force depression during 
fatigue. The initial decline in myofibrillar maximal Ca2+-activated force is not 
seen in mouse muscle fibres deficient of creatine kinase where there is little 
change in Pi (Dahlstedt et al., 2000), and Pi depresses tetanic force in skinned 
fibres (Pate & Cooke, 1989; Millar & Homsher, 1990). The reduction in tetanic 
[Ca2+]i is believed to mainly stem from perturbed SR Ca2+ release resulting from 
Ca2+-Pi precipitation in the SR (Fryer et al., 1995; Westerblad & Allen, 1996), and 
the combined effects of reduced cytosolic [ATP] and increased cytosolic free 
[Mg2+], which inhibits the RyR1 channel (Blazev & Lamb, 1999). Accordingly, 
the fall in tetanic [Ca2+]i is greatly delayed when creatine kinase is inhibited in 
rodent fibres (Dahlstedt & Westerblad, 2001), and injection of Pi into single intact 
mouse fibres causes a marked fall in SR Ca2+ release and tetanic force 
(Westerblad & Allen, 1996).  Reduced myofibrillar Ca2+ sensitivity is caused by 
an accumulation of Pi and a reduction in intracellular pH (pHi), but may also be 
modulated by reactive oxygen and nitrogen species (RONS) (Dahlstedt et al., 
2001; Allen et al., 2008; Lamb & Westerblad, 2011).  
Intramuscular acidosis and skeletal muscle fatigue development 
In exercising humans, pHi has been reported to fall ∼0.5 pH units following 
intense muscle activity (Sahlin et al., 1975; Sahlin et al., 1976; Bangsbo et al., 
1996). Historically, intramuscular acidosis has been acclaimed a major role in the 
force decline during fatigue (Fitts, 2016). The underlying observations supporting 
this view include observations from exercising humans and studies from isolated 
animal muscle fibres.  
Initial studies found a good temporal correlation between intramuscular 
acidification and fatigue (Dawson et al., 1978). In coherence with this finding, a 
reduction in maximal Ca2+-activated force was demonstrated upon acidification of 
isolated animal muscles (Donaldson et al., 1978; Fabiato & Fabiato, 1978). This 
notion was later challenged as the force-depressive effect of acidification was 
found to be highly temperature-dependent and to be blunted when studied at 
physiological temperatures (Pate et al., 1995; Westerblad et al., 1997). Notably, 
the fatigue tolerance of isolated rodent fibres fatigued under acidic conditions was 
unaltered when studied at near-physiological temperatures (Bruton et al., 1998).  
Recovery from fatigue 
Recovery of force producing capacity following fatigue follows a time course that 
is largely dependent on the metabolic properties of the muscle fibre. While 
oxidative slow-twitch fibres recover their force producing capacity nearly 
instantly, fast-twitch fibres recover more slowly (Allen et al., 2008). In fast-twitch 
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fibres it is possible to discern a difference in the time course for recovery 
depending on the frequency of stimulation used to initiate contraction. At high-
frequency stimulation (80-100 Hz) recovery from fatigue occurs within minutes, 
while at low-frequency stimulation (20-30 Hz) recovery is not complete until 
several hours (Edwards et al., 1977; Bruton et al., 2008). This delayed force 
recovery at low frequencies has been termed prolonged low-frequency force 
depression (PLFFD).  
Theoretically, PLFFD could be caused by an impaired SR Ca2+ release and/or 
reduced myofibrillar Ca2+ sensitivity. This is explained by the non-linear force-
[Ca2+]i relation, which is flat at high- while steep at low-stimulation frequencies. 
Hence, a reduction in tetanic [Ca2+]i or a decrease in myofibrillar Ca2+ sensitivity 
will result in a more marked force reduction at low- than at high-frequencies 
(Westerblad et al., 1993; Bruton et al., 2008; Cheng et al., 2015). The relative 
contribution of the two underlying causes of PLFFD varies with recovery time 
(Watanabe et al., 2015; Watanabe & Wada, 2016) and experimental species 
(Bruton et al., 2008). 
Models to study skeletal muscle Ca2+-handling, force 
and fatigue 
Attempts to address the mechanisms behind skeletal muscle fatigue have 
employed experimental models that range from exercising humans to isolated 
single myofibrils (Lamb, 2002; Allen et al., 2008). Given the central role of 
intracellular Ca2+ in the physiological events responsible for skeletal muscle force 
generation and fatigue development, experimental models that enable continuous 
recordings of [Ca2+]i and force are best suited for such mechanistic studies. At the 
time this thesis work commenced, intact single fibres isolated from animal 
muscles were the only model to entirely fulfil these requirements (Place et al., 
2010). Due to the possibility of species differences, it was unknown to what 
extent findings in animal models would translate to the human setting. Alternative 
experimental models enabling studies of human skeletal muscle cells included in 
vivo studies, skinned skeletal muscle fibres, and cultures of myoblasts and 
myotubes. However, as will be alluded to next, inherent limitations of these 
models have limited their applicability in mechanistic studies of intracellular 
Ca2+-handling and force production. 
Human skeletal muscle in vivo  
The intact human skeletal muscle in vivo with maintained blood supply, neural 
innervation of motor units and, often, mixture of fibre types, extracellular matrix 
and tendinous attachments intact is arguably the gold standard for experiments on 
human muscle functions. In the early 1950’s, non-invasive experimental protocols 
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were developed to study human fatigue by analysing the reduction in maximal 
voluntary force following isometric contractions (Merton, 1954). Later, the 
possibility of EMG and percutaneous stimulation of the motor nerve or the 
muscle itself enabled the differentiation of peripheral and central components of 
human muscle fatigue (Bigland-Ritchie et al., 1978). The muscle biopsy 
technique (Bergström, 1962), and non-invasive nuclear magnetic resonance 
spectroscopy (Sapega et al., 1987), made it possible to study the correlation of 
skeletal muscle metabolic and ionic changes with fatigue development. Despite 
these advances, it remains difficult to distinguish between the different factors 
that may contribute to fatigue in human skeletal muscle in vivo experiments 
(Allen et al., 2008). For these types of mechanistic studies, direct assessments of 
changes in [Ca2+]i in parallel with measurements of force are genereally 
considered necessary. Techniques that enable this type of studies in humans in 
vivo are yet to be developed.  
Isolated intact single skeletal muscle fibres 
Intact single skeletal muscle fibres can be isolated from animal muscles by either 
enzymatic dissociation or manual dissections. While the former represents a 
relatively straightforward procedure to obtain several muscle fibres per muscle 
bundle, the latter is a tedious dissection using forceps, micro-scissors and 
microscopes to obtain a single intact muscle fibre (Cheng & Westerblad, 2017). 
The great advantage of the latter approach is that, while the tendons are lost 
during enzymatic dissociation, they remain intact following manual dissection. 
This allows mounting of the muscle fibre in a force transducer making force 
recordings possible. Fluorescent Ca2+ indicator dyes can be introduced into viable 
muscle fibres, which enable continuous measurements of force and [Ca2+]i in 
living muscle fibres (Place et al., 2010; Cheng & Westerblad, 2017).  
Skinned skeletal muscle fibres 
Skinned skeletal muscle fibres are muscle fibres in which the sarcolemma has 
been disrupted or removed. This can be achieved either by chemical 
permeabilisation of the sarcolemma or by mechanically removing the sarcolemma 
(Lamb, 2002). The major advantage of the skinned muscle fibre model is that it 
does not require that intact muscle fibres be collected, which can be difficult to 
nearly impossible depending on the size of the muscle (Cheng & Westerblad, 
2017). Notably, skinned muscle fibres can be obtained from, e.g., percutaneous 
muscle biopsies, enabling studies in human skeletal muscle (Place et al., 2010).  
Limitations of this model include a loss of soluble cytosolic proteins and the 
naturally occurring build-up of metabolic by-products that may be of importance 
in fatigue development. Skinned fibre experiments are generally conducted at 
temperatures lower than those prevailing in vivo and, as alluded to earlier, this 
may be problematic when considering the mechanistic aspects of fatigue (Lamb, 
2002; Allen et al., 2008). In addition, although feasible in the less used model of 
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mechanically skinned fibres (Posterino et al., 2000), the standard procedure of 
chemically skinned fibres does not allow for analysis of SR Ca2+ release and 
excitation-contraction coupling (Lamb, 2002; Allen et al., 2008). 
Myoblasts and myotubes 
Satellite cells are skeletal muscle resident stem cells involved in the maintenance 
and adaptive processes of skeletal muscle tissues (Mauro, 1961; Relaix & 
Zammit, 2012). Satellite cells can be extracted from human muscle biopsies, 
activated into proliferating myoblasts and differentiated into multinuclear 
myotubes ex vivo (Blau & Webster, 1981). Upon differentiation of myoblasts into 
myotubes, several morphological, metabolic and biochemical features similar to 
those in adult skeletal muscle fibres have been reported (Berggren et al., 2007; 
Aas et al., 2013). This together with the advantage that myotubes retain donor-
specific traits have rendered myotubes a widely used ex vivo model of human 
skeletal muscle (Peter et al., 2009; Ullrich et al., 2011; Nikolic et al., 2012; Aas et 
al., 2013; Scheler et al., 2013). However, differences in metabolic (Sarabia et al., 
1992; Baker et al., 2003), contractile and intracellular Ca2+-handling properties 
(Tanaka et al., 2000; Bandi et al., 2008; Rokach et al., 2013; Cheng et al., 2014; 
Smith et al., 2014; Madden et al., 2015) have been reported between myotubes 
and muscle fibres. These limitations cast doubt as to whether findings in 
myotubes are transferrable to the adult muscle fibre. 
Intrinsic skeletal muscle changes in disease  
Disease-related changes affecting skeletal muscle force producing capacity and 
fatigue resistance may occur at any level from the brain to the contractile proteins. 
Although likely the result of a combination of factors, it is clear that changes 
intrinsic to the skeletal muscle contributes to the loss of skeletal muscle function 
in patients suffering from chronic diseases including heart failure and rheumatoid 
arthritis (Middlekauff, 2010; Yamada et al., 2017; Steinz et al., 2019), but also in 
patients afflicted by acute critical illness myopathy (Friedrich et al., 2015).   
In heart failure patients, this is demonstrated by the finding of a remaining 
muscle force deficit when force is normalized to muscle cross sectional area, leg 
muscle mass, or body weight (Lipkin et al., 1988; Harrington et al., 1997; Toth et 
al., 2006; Toth et al., 2010; Toth et al., 2012). A similar qualitative decline in 
muscle function is found in rheumatoid arthritis and critical illness myopathy 
patients (Helliwell & Jackson, 1994; Friedrich et al., 2015), and rodent disease 
models (Yamada et al., 2009; Yamada et al., 2015a; Yamada et al., 2015b; Llano-
Diez et al., 2016; Steinz et al., 2019). 
  9 
Intracellular Ca2+-handling and disease-related muscle 
dysfunction  
Altered intracellular Ca2+-handling has been implicated in disease-related 
quantitative and qualitative changes in skeletal muscle. Changes in intracellular 
Ca2+-handling may involve principally two steps in the excitation-contraction 
coupling process that would directly affect muscle contractile function and 
resistance to fatigue: (i) the release/reuptake of SR Ca2+ and (ii) the myofibrillar 
Ca2+ sensitivity. Additionally, changes in basal [Ca2+]i or [Ca2+]i transient 
amplitude and/or duration regulate, e.g., muscle protein metabolism and the 
amount of contractile proteins available for force production (Bhattacharyya et 
al., 1993; Menconi et al., 2004; Smith & Dodd, 2007; Dridi et al., 2020; Kushnir 
et al., 2020). 
A reduction in SR Ca2+ release and decreased myofibrillar Ca2+ sensitivity has 
been found to contribute to the muscle weakness observed in animal models of 
heart failure (Perreault et al., 1993; Reiken et al., 2003; Ward et al., 2003), 
rheumatoid arthritis (Yamada et al., 2009; Yamada et al., 2015b), critical illness 
myopathy (Callahan et al., 2001; Llano-Diez et al., 2016), and normal ageing 
(Andersson et al., 2011). Due to technical difficulties, mechanistic studies of this 
sort in humans are scarce. However, perturbed action potential-evoked Ca2+ 
transient amplitude and release in isolated skeletal muscle fibre segments from 
heart failure patients have been reported (DiFranco et al., 2014). Additionally, the 
quantity and extent of posttranslational modifications of intracellular Ca2+-
handling proteins differ between human heart failure patients and controls, 
indicating plausible differences in functional Ca2+-handling properties 
(Middlekauff et al., 2012; Rullman et al., 2013) in this patient group.  
Causes of disease-related changes in intracellular Ca2+-
handling  
Studies in animal models have demonstrated that a loss of skeletal muscle mass 
and function, related to altered intracellular Ca2+-handling, is manifested in 
several diseases of otherwise different underlying aetiology (Reiken et al., 2003; 
Yamada et al., 2015b; Llano-Diez et al., 2016). It is possible that factors not 
related to the disease process in itself, e.g., muscle disuse, or processes unique for 
each disease may explain these common manifestations. An alternative 
hypothesis is that the inherent biological response to several diseases shares 
common features, and that these contribute to the impaired muscle function. In 
support for this, several of these diseases exhibit common features, such as an 
increased neuroendocrine activation, elevated circulating levels of pro-
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inflammatory cytokines, and altered sphingolipid metabolism (Andersson & 
Marks, 2010; Nikolova-Karakashian & Reid, 2011; Reid & Moylan, 2011). In 
animal models, these have all been demonstrated to induce changes in skeletal 
muscle intracellular Ca2+-handling and to impair muscle function.  
Neuroendocrine activation 
Posttranslational modifications of RyR1, including phosphorylation, oxidation 
and nitrosylation, have been demonstrated in human heart failure patients 
(Rullman et al., 2013). In animal models, these modifications have been shown to 
result in dissociation of the stabilising protein FKBP12 from RyR1, increasing the 
leakage of SR Ca2+ into the cytosol. This is turn causes an elevation in baseline 
[Ca2+]i and a depletion of SR Ca2+, ultimately causing a reduction in tetanic [Ca2+]i 
amplitude and subsequent force decline (Ward et al., 2003). Excessive 
neuroendocrine activation in heart failure has been suggested to cause skeletal 
muscle weakness and fatigue intolerance due to hyperphosphorylation of RyR1 
via β-adrenergic activation (Reiken et al., 2003).  
Cytokines 
A number of circulating proinflammatory cytokines are elevated in heart failure, 
rheumatoid arthritis and critical illness myopathy. Of these, TNFα is the cytokine 
most widely recognized to correlate with disease severity and poor prognosis 
(Rauchhaus et al., 2000; Conraads et al., 2003; Friedrich et al., 2015). Albeit 
other circulating cytokines are elevated in these conditions, the correlation of 
these cytokines to muscle dysfunction and prognosis is weaker and more 
ambiguous (Testa et al., 1996; Friedrich et al., 2015). Increased levels of 
circulating TNFα, or soluble forms of TNF receptor I or II, which are believed to 
reflect an increased activity of TNFα, are elevated in heart failure (Levine et al., 
1990; Torre-Amione et al., 1996; Rauchhaus et al., 2000), and especially so in the 
most symptomatic heart failure patients (i.e. NYHA class III-IV) (Ferrari et al., 
1995; Testa et al., 1996; Torre-Amione et al., 1996; Rauchhaus et al., 2000; 
Deswal et al., 2001), and in cachectic patients (Levine et al., 1990).  
Exogenously administered TNFα depresses cardiomyocyte force by reducing 
tetanic [Ca2+]i (Yokoyama et al., 1993). In skeletal muscle, TNFα has been 
demonstrated to reduce membrane excitability suggesting that it may inactivate 
DHPR and thus reduce tetanic [Ca2+]i and force (Tracey et al., 1986). Later 
studies in isolated rodent skeletal muscle fibres have shown that TNFα acutely 
reduces tetanic force without affecting tetanic [Ca2+]i (Reid et al., 2002), by a 
RONS-dependent mechanism (Reid et al., 2002; Stasko et al., 2013). Notably, 
changes in intracellular Ca2+-handling via RONS-induced modifications of the 
RyR1 have been suggested in human heart failure patients (Rullman et al., 2013).  
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Sphingolipid metabolism and sphingomyelinase activity  
The sphingomyelinase family is a group of biochemically and genetically 
different enzymes, all of which hydrolyse sphingomyelin to ceramide and 
phosphorylcholine (Nikolova-Karakashian & Reid, 2011). Circulating 
sphingomyelinase activity is elevated in human heart failure (Doehner et al., 
2007), rheumatoid arthritis (Hanaoka et al., 2018) and critical illness myopathy 
patients (Claus et al., 2005). In heart failure patients, circulating 
sphingomyelinase activity is positively correlated to both circulating TNFα and 
TNF-RI while negatively correlated to muscle strength measures and lean tissue 
mass (Doehner et al., 2007). Moreover, circulating sphingomyelinase activity is 
increased in a stepwise fashion according to NYHA class while related to 
impaired survival, independent of age, NYHA class or mean blood pressure 
(Doehner et al., 2007). Similarly, an elevation of sphingomyelinase activity 
predicts a worse outcome in patients treated at the intensive care unit, while 
inhibition of sphingomyelinase activity has been found to increase survival in a 
mouse model of endotoxic shock (Claus et al., 2005).  
In rodent skeletal muscle, exogenous sphingomyelinase increases ceramides 
and oxidant activity while perturbing force production (Ferreira et al., 2010; 
Ferreira et al., 2012; Loehr et al., 2014; Bost et al., 2015), and fatigue resistance 
(Ferreira et al., 2010; Ferreira et al., 2012; Loehr et al., 2014). Sphingomyelinase-
induced attenuation of force has been suggested to result from changes in 
maximum Ca2+-activated force and a reduction in myofibrillar Ca2+ sensitivity 
(Ferreira et al., 2012). The current hypothesis is that increased levels of pro-
inflammatory cytokines and RONS contribute to perturbed muscle function in 
diseases characterized by elevated sphingomyelinase activity via 
sphingomyelinase-dependent effects on skeletal muscle force producing capacity 
and fatigue resistance (Marathe et al., 1998; Wong et al., 2000; Jenkins et al., 
2010; Nikolova-Karakashian & Reid, 2011; Moylan et al., 2014). 
Disease-related loss of muscle mass 
Disease-related loss of muscle mass results in a dismal life quality and has been 
reported as an independent risk factor for mortality (Anker et al., 1997; Hulsmann 
et al., 2004; Sokka et al., 2008; Chung et al., 2014; Powers et al., 2016). The net 
protein balance, i.e. the ratio of protein synthesis and degradation, dictates muscle 
fibre size (Phillips et al., 2012). When muscle protein degradation exceeds 
synthesis, muscle protein depletion ensues and the muscle fibre atrophies. At the 
whole tissue level, muscle atrophy may also be caused by the loss of individual 
muscle fibres (Wilkinson et al., 2018). In several diseases, both a negative protein 
balance and a loss of muscle fibres have been shown to contribute to the loss of 
muscle mass (Powers et al., 2016). Disease-related modifications of Ca2+-
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regulated process have been postulated to trigger these changes (Bhattacharyya et 
al., 1993; Menconi et al., 2004; Smith & Dodd, 2007; Dridi et al., 2020; Kushnir 
et al., 2020). 
A third potential cause of disease-related muscle atrophy is a reduced 
hypertrophic response and regenerative capacity of the skeletal muscle due to 
perturbed muscle stem cell function and abundance (McKenna & Fry, 2017; 
Wilkinson et al., 2018). Muscle stem cell functions are regulated by local and 
systemic factors that modulate their proliferation and differentiation. One such 
factor that has increasingly been linked to skeletal muscle health and intimately 
linked to the regulation of muscle stem cell functions is vitamin D (Girgis et al., 
2013; Girgis et al., 2014a). 
The role of vitamin D in skeletal muscle physiology 
and pathology 
Deficiency of Vitamin D is a widely spread and highly prevalent condition, and 
has been associated with skeletal muscle weakness and atrophy (Girgis et al., 
2013). The major circulating form of vitamin D consists of 25(OH)D, which is 
believed to be biologically inactive. 25(OH)D is hydroxylated by the enzyme 1α-
hydroxylase, present in the proximal tubules of the kidney, to form the 
biologically active 1α,25(OH)2D. The half-life of 1α,25(OH)2D is short, and the 
synthesis strictly controlled so that serum levels are usually well maintained 
despite very low levels of 25(OH)D (Need et al., 2008). Assessment of vitamin D 
status is therefore made by measuring the serum concentration of 25(OH)D, upon 
which the diagnosis of vitamin D deficiency is made (Hollis & Wagner, 2005).  
The vitamin D receptor has been reported to be present in virtually all cells of 
the body, including some reports claiming its presence in human skeletal muscle 
fibres (Pojednic et al., 2015). Proposed effects of vitamin D in skeletal muscle 
include an increase in force generation via non-genomic actions on intracellular 
Ca2+-handling, and an anabolic response via transcriptional regulation (Girgis et 
al., 2013; Bass et al., 2020). In rodent muscles, overexpression of the vitamin D 
receptor induces a hypertrophic response by stimulating protein synthesis, and 
possibly muscle stem cell number and activity (Bass et al., 2020). Notably, 
vitamin D has been suggested to reduce the expression of myostatin, a well-
established negative regulator of muscle mass (McPherron et al., 1997), in rodent 
skeletal muscle cells (Garcia et al., 2011; Girgis et al., 2014a). However, a direct 
effect of vitamin D on skeletal muscle cells has been a subject of controversy, 
with even the presence of the vitamin D receptor in the skeletal muscle tissue in 
question (Wang & DeLuca, 2011; Bouillon et al., 2014; Pike, 2014). 
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2 Objectives and outline of the thesis 
The overarching aim of the current thesis was to study the intracellular 
mechanisms of human muscle fatigue and disease-related loss of muscle 
function and mass. A special focus was put on the tentative role of altered 
intracellular Ca2+-handling in these processes. An integrative approach spanning 
from single intact muscle fibres, isolated muscle stem cells, to whole muscle 
biopsies from healthy and diseased individuals was employed.  
 
 
 
The specific aims of the studies were as follows: 
 
Study I To establish an experimental model suitable for mechanistic studies 
of intracellular Ca2+-handling, force generation and fatigue in 
human skeletal muscle.  
 
Study II To test the hypothesis that vitamin D plays a role in maintaining 
human skeletal muscle function and mass by regulating muscle 
stem cell functions. 
 
Study III To investigate the cellular mechanisms of human muscle fatigue 
and the effects of acidosis on muscle performance. 
 
Study IV To test the hypothesis that elevated sphingomyelinase activity is 
implicated in disease-related loss of muscle function and mass by 
affecting intracellular Ca2+-handling and muscle atrophy processes.
   
 
 
 

  15 
3 Summary of study results  
The following section provides a summary of the key results of studies I-IV. For 
detailed results the reader is referred to the individual studies presented in sections 
four to seven. 
Study I: Ex vivo models of human skeletal muscle 
In study I, we took advantage of the relatively short muscle fibres of the accessory 
respiratory muscles located between the ribs of humans, the intercostal muscles, 
to manually dissect intact single fibres. During thoracotomies performed for 
medical reasons, the intercostal muscles are exposed and dissected to access the 
thoracic cavity. Thus, they are accessible for muscle biopsies without 
unwarranted inconvenience or additional risk for the patient. By this approach we 
obtained intact single human muscle fibres that enabled electrically evoked 
contractions, while continuously measuring [Ca2+]i and force. Human myoblasts, 
isolated from vastus lateralis muscle biopsies, were differentiated ex vivo to 
form myotubes, and their contractile function and Ca2+-handling characteristics 
were compared to those of adult intercostal muscle fibres.  
Upon differentiation, human myoblasts fused to form multinucleated 
myotubes with an increased expression of Ca2+-handling proteins and 
functionality of the initial events of the excitation-contraction coupling cascade. 
Increased expression of contractile proteins and initiation of structural 
organisation were also evident upon differentiation. Yet, we found major 
remaining differences when compared to the adult muscle fibre: none of the 
myotubes contracted, and the Ca2+ transient decay upon electrical stimulation was 
markedly prolonged in myotubes (Figure 3.1A-B). Subsequent analyses 
suggested that these remaining differences were due to dissimilarities in regards 
to the protein abundance and co-localisation of Ca2+-handling proteins, and 
ultrastructure (Figure 3.1C-D).  
The duration of [Ca2+]i transients have been demonstrated to affect the cellular 
signalling initiated by increased [Ca2+]i (Berridge, 1990, 1992; Dolmetsch et al., 
1997; Berridge et al., 2003; Clapham, 2007; Tavi & Westerblad, 2011). Thus, 
when studying Ca2+-dependent processes such as gene expression and 
metabolism, myotubes are likely to provide different answers to those given by 
intact adult muscle fibres.  
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Figure 3.1. Human muscle fibres and myotubes showed marked differences in Ca2+-
handling characteristics and contractile ability. Changes in Ca2+ indicator dye intensity 
(A) and force (B) following electrical stimulation of a human muscle fibre, myotube and 
myoblast. Fluorescent intensity for RyR and DHPR (C), and TEM images of the 
ultrastructure (D) in a human muscle fibre and myotube. Note the characteristic 
arrangement of myofibrils separated by triads (arrow) at the junction of the A and I bands 
in fibres while only rudimentary myofilament structures (*) were seen in myotubes.  
Study II: Effects of vitamin D in human skeletal muscle  
Contemplating previous findings and the results in study I, we considered 
human myoblasts, myotubes and muscle fibres to represent distinct stages of 
muscle development. In study II, we took advantage of this to investigate the 
presence of components of the vitamin D endocrine system, including the 
vitamin D receptor, and the vitamin D metabolising enzymes CYP24A1 and 
CYP27B1, in human muscle cells at different developmental stages. The effects 
of vitamin D on the regulation of processes involved in muscle regeneration and 
growth were investigated in human myoblasts. 
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The vitamin D receptor was readily detectable in human myoblasts and 
myotubes, while non-detectable in human adult skeletal muscle (Figure 3.2A). 
Attention was therefore focused on the effects of vitamin D on human myoblast 
proliferation and differentiation. Results revealed a profound inhibitory effect 
by the biologically active form of vitamin D (1α,25(OH)2D) on myoblast 
proliferation and differentiation. No effects by the biologically inactive form 
25(OH)2D were detected in human myoblasts (Figure 3.2B).  
 
Figure 3.2. The vitamin D receptor was readily detected in human muscle stem cells 
and vitamin D markedly inhibited human myotube formation. A, protein quantity of 
the vitamin D receptor (VDR) in human primary myoblasts, myotubes and adult skeletal 
muscle. B, fusion index following 8 days of differentiation in the presence of 1 nM or 100 
nM 1α,25(OH)2D3, or 100 nM 25(OH)D3. Data are presented as the mean ±SEM. 
*P<0.05, **P<0.01. (ND) = non-detectable. 
 
 
Global gene expression analysis provided mechanistic insight by 
demonstrating an altered expression of cell cycle regulators consistent with a 
block of cell cycle progression at the G1/S restriction point. Further, vitamin D 
reduced the expression of MyoD, myogenin and MEF2C, myogenic regulatory 
factors acknowledged for their role in muscle stem cell commitment and 
differentiation (Relaix & Zammit, 2012). Gene-ontology enrichment of down-
regulated genes identified GO categories involved in ‘muscle organ 
development’. Network analysis using IPA identified pathways annotated as 
‘differentiation of myoblasts’ and ‘differentiation of muscle cells’ among the 
most highly inhibited biological functions. Altered expression of genes 
intimately involved in muscle stem cell self-renewal lead us to suggest a role of 
the biologically active form of vitamin D in the maintenance of the muscle stem 
cell pool (Figure 3.3).  
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Figure 3.3. Illustration of the results from studies I and II. Vitamin D promotes 
satellite cell self-renewal while inhibiting myoblast differentiation. Activated myoblasts 
form myotubes both in vivo and ex vivo, but only in vivo do myotubes fully mature into 
muscle fibres with functional excitation-contraction (E-C) coupling and contractile ability. 
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Study III: Cellular mechanisms of human skeletal 
muscle fatigue 
In study III, the cellular mechanisms of human muscle fatigue following near 
maximal isometric contractions were investigated by continuous measurements 
of force and [Ca2+]i transients. Based on their ability to maintain force >40% of 
the unfatigued value during 500 tetani, two distinct groups of fibres were 
distinguished: fatigue sensitive and fatigue resistant.  
In both groups of fibres, the fatigue-induced force loss was primarily caused 
by an impaired SR Ca2+ release, while the myofibrillar Ca2+ sensitivity was either 
unaltered (fatigue-sensitive fibres) or increased (fatigue-resistant fibres) (Figure 
3.4). Integrating these results, fatigue development in human muscle fibres is 
different to that in rodent muscle fibres in that reduced myofibrillar Ca2+ 
sensitivity plays no role in the force loss in human fibres.  
 
 
 
 
 
Figure 3.4. Illustration of the cellular mechanisms of fatigue in human muscle fibres. 
A and B, contractile-induced changes in tetanic force, [Ca2+]i and force-[Ca2+]i relationship 
in human fatigue-sensitive and fatigue-resistant muscle fibres, respectively. Note that in 
both human fatigue-sensitive and fatigue-resistant fibres the main cause of fatigue was a 
reduced SR Ca2+ release while myofibrillar Ca2+ sensitivity was either unaltered (fatigue-
sensitive fibres) or increased (fatigue-resistant fibres) following fatigue.   
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In fatigue-resistant fibres, recovery was complete 15 minutes after cessation of 
fatiguing contractions. In contrast, in fatigue-sensitive fibres the force at low-
frequency stimulation was markedly lower, while force at high-frequency 
stimulation was recovered, compared to the unfatigued value. This phenomenon, 
known as prolonged low-frequency force depression (PLFFD), was exclusively 
due to an impaired SR Ca2+ release. Myofibrillar Ca2+ sensitivity and maximal 
force producing capacity was unaltered (Figure 3.5). Cumulatively, these results 
demonstrate a fundamental importance of impaired SR Ca2+ release to the force 
depression following fatigue and in the early recovery period in human muscle 
fibres.  
 
 
Figure 3.5. PLFFD in human muscle fibres was caused exclusively by an impaired 
SR Ca2+ release. A, representative force and [Ca2+]i records in a fatigue-sensitive muscle 
fibre at low- and high-frequency stimulation before (unfatigued) and 15 min after 
(recovery) fatiguing stimulation. C, PLFFD was evident in human fatigue-sensitive 
muscle fibres. D, the force decline in fatigue-sensitive fibres during recovery followed the 
unfatigued force-[Ca2+]i relationship with force fully restored to unfatigued levels in the 
presence of 5 mM caffeine. Data are means ± SEM. * P < 0.05, ** P < 0.01. 
 
 
Intracellular acidosis has historically been ascribed a major causative role in 
the fatigue-induced force loss following intense contractile activity (Fitts, 2016). 
However, as alluded to previously, this view has later been challenged by findings 
in animal isolated muscles studied at or near physiological temperatures (Pate et 
al., 1995; Westerblad et al., 1997; Bruton et al., 1998). We were therefore 
interested in the effects of intracellular acidosis on the force-[Ca2+]i relation and 
fatigue resistance of human fibres at 37° C. In unfatigued human muscle fibres, 
intracellular acidosis reduced the myofibrillar Ca2+ sensitivity, but this was 
completely offset by an increase in tetanic [Ca2+]i so that force was maintained 
(Figure 3.6A-B). Results further suggested that the fatigue-resistance of human 
fibres was unaltered upon acidification (Figure 3.6C-D).  
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Figure 3.6. Acidosis did not reduce force production, nor decrease the fatigue 
tolerance of human intercostal muscle fibres. A, representative [Ca2+]i and force records 
in a human muscle fibre during a 30 Hz and 70 Hz tetanus under control (5% CO2) and 
acidic (30% CO2) conditions. B, acidification resulted in increased tetanic [Ca2+]i while 
force production was unaltered. C and D, number of tetanic contractions required to reach 
40% of the initial force in fatigue-sensitive (C) and fatigue-resistant (D) human fibres. 
Data are means with individual data points as well as the 90% confidence interval of the 
group mean difference (C and D). Adjoining lines indicate data points from paired 
experiments. * P < 0.05, ** P < 0.01. 
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Study IV: The role of sphingomyelinase in disease-
related loss of muscle function and mass  
In study IV, the effects of sphingomyelinase on the force production, Ca2+-
handling, and transcriptional regulation of genes related to muscle atrophy 
processes were studied in intact muscle fibres. The activity of sphingomyelinase 
was measured in skeletal muscle from human heart failure and healthy age-
matched subjects, and related to circulatory markers of inflammation and 
factors of known prognostic value in heart failure, previously reported by our 
lab for the current patient cohort (Rullman et al., 2020).  
The results show that sphingomyelinase activity impaired SR Ca2+ release and 
reduced myofibrillar Ca2+ sensitivity to depress force in intact human muscle 
fibres (Figure 3.7).  
 
 
 
 
Figure 3.7. Illustration of the effects of sphingomyelinase on muscle fibre force and 
Ca2+-handling. Sphingomyelinase-induced changes in tetanic force and [Ca2+]i (A) and in 
the force-[Ca2+]i relationship (B) in human intact muscle fibres. Sphingomyelinase activity 
reduced myofibrillar Ca2+ sensitivity (i) and decreased tetanic [Ca2+]i (ii). SMase, 
sphingomyelinase. 
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In human muscle bundles, sphingomyelinase induced the transcription of 
genes of the ubiquitin-proteasome system, including essential subunits of the 
proteasome 20s core (PSMB5, 6, 7 and PSMA4), the 19s regulator (PSMC 1, 3, 
4, 5 and PSMD1), polyubiquitin B and C (Figure 3.8A). Meanwhile, transcripts 
of ribosomal proteins (Figure 3.8B), factors implicated in muscle proliferation, 
and cellular locomotion were reduced by sphingomyelinase.  
 
 
 
 
Figure 3.8. Sphingomyelinase activity induced transcriptional changes promoting 
muscle atrophy in human intact muscle fibres. Barcode-plots showing 
sphingomyelinase-induced changes in factors involved in proteasome degradation (A) and 
ribosomal proteins (B). In the lower panel each regulated gene of interest is depicted as a 
vertical line on the corresponding ratio (blue panel depicts down-regulated and red up-
regulated genes) in treated vs. control-muscle. The upper panel depicts the enrichment of 
fold-changes between treated vs. control-muscle. 
 
 
 
In human heart failure patients, the activity of intramuscular neutral 
sphingomyelinase (Figure 3.9A), but not acid sphingomyelinase, was increased 
as compared to age-matched healthy controls. In the cohort of patients included in 
the longitudinal axis of the study, both neutral (Figure 3.9B) and acid 
sphingomyelinase activity were found to increase with duration of disease. 
Intramuscular neutral sphingomyelinase activity positively correlated with 
circulatory markers of inflammatory activation and atrophy including TNF-RI 
and II, and markers previously demonstrated to carry prognostic value in this 
patient cohort (Rullman et al., 2020), including NT-proBNP, IGFBP7 and 
GDF15 (Figure 3.9C).  
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Figure 3.9. Intramuscular neutral sphingomyelinase activity is elevated in human 
heart failure and correlates to circulatory markers of inflammation and muscle 
atrophy. A, skeletal muscle nSMase activity in human heart failure patients and healthy 
age-matched controls. C, skeletal muscle nSMase activity in human heart failure patients 
at the time of the baseline biopsy (time of inclusion in the study) and at the follow-up 
biopsy. Mean follow-up time 2.5 (± 0.2) years. Bars indicate mean value and circles 
represent individual data points. C, correlation of skeletal muscle nSMase activity and 
serum protein quantities of factors analysed with targeted proteomics in human heart 
failure patients (n = 61) where edges denote correlation coefficients >0.3. nSMase, neutral 
sphingomyelinase. 
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8 Discussion and implications  
This thesis investigated the cellular mechanisms underlying human muscle 
fatigue and disease-related muscle dysfunction, with a special focus on Ca2+-
regulated processes. Novel contributions include a mechanistic insight into the 
underlying causes of fatigue in human muscle fibres, the direct effects of vitamin 
D in muscle, and the role of sphingomyelinase in disease-induced muscle 
weakness and atrophy.  
Ex vivo models of human skeletal muscle 
At the time this thesis work commenced, manually dissected single fibres were 
arguable still the best model for mechanistic studies of muscle fibre functions. An 
obvious drawback of this model is the inferred problem of species differences, 
i.e., can we be sure that the findings in rodent muscles are representative of those 
in human muscles? A tentative approach to overcome this issue is the use of 
differentiated human myotubes. These can be obtained from minimally invasive 
muscle biopsies (Blau & Webster, 1981), and have been acclaimed traits that are 
similar to muscle fibres. In addition, they have been shown to retain donor-
specific qualities (Berggren et al., 2007; Aas et al., 2013). The possibility to study 
disease-related changes in human muscle cells spurred our interest to investigate 
the utility of myotubes for studies of muscle fibre functions.  
In study I, myotubes were found to develop some fibre-like qualities, but they 
did not develop functional excitation-contraction coupling. Hence, at least using 
the 2D culture protocol employed in study I, myotubes were found to be an 
inadequate model for studies of these muscle fibre functions. At the time of study 
I and in the years that followed, 3D cultures and continuous electrical stimulation 
were demonstrated to ameliorate the development of functional excitation-
contraction coupling in myotubes (Madden et al., 2015; Rao et al., 2018; 
Khodabukus et al., 2019). Despite this, major differences in force production and 
Ca2+ transient kinetics were still apparent between these bioengineered myotubes 
and muscle fibres. Manually dissected single fibres from human intercostal 
muscles were therefore chosen in the following studies of adult muscle fibre 
functions in this thesis. However, the technical difficulties related to the 
dissection and the dependence of surgical procedures makes this a time-
consuming and low-throughput model. Continuous efforts to develop ex vivo 
models of human myotubes amenable for studies of muscle fibre contraction and 
Ca2+-handling are therefore anticipated and warranted. 
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Effects of vitamin D in human skeletal muscle 
In study II, we found components of the vitamin D endocrine system were 
abundant in human muscle stem cells, while low to non-detectable in adult 
skeletal muscle. The apparent lack of the VDR in adult muscle fibres contrasts 
some previous reports in human and rodent skeletal muscle (Simpson et al., 1985; 
Costa et al., 1986; Bischoff et al., 2001; Pojednic et al., 2015). The reason for this 
disparity is likely due to differences in the antibody used to detect the VDR. 
Notably, when using the stringently validated VDR D-6 antibody, Wang and 
DeLuca (2011) reported that the VDR was un-detectable in skeletal muscle fibres, 
while confirming unspecific binding of other commercially available antibodies 
(Wang & DeLuca, 2011). While this does not exclude a direct role of vitamin D 
in muscle fibres, these findings suggest direct effects of vitamin D in human 
skeletal muscle to predominantly involve muscle stem cells. 
Coherent with such a role, results in study II demonstrated a robust direct 
effect of vitamin D in human muscle stem cells: the biologically active 
1α,25(OH)2D3, but not 25(OH)D3, inhibited human myoblast proliferation and 
differentiation. This marks a contribution to the literature, as previous studies 
have been limited to animal muscle stem cells (Garcia et al., 2011; Srikuea et al., 
2012; Girgis et al., 2014a; Girgis et al., 2014b).  
In order to maintain the skeletal muscle stem cell pool, part of the myoblast 
progeny must return to quiescence by events inhibiting myoblast proliferation and 
differentiation (Kuang et al., 2007). This process is controlled by the FOXO3 and 
Notch signalling pathways (Kuang et al., 2007; Bjornson et al., 2012; Gopinath et 
al., 2014), both of which we found to be modulated by vitamin D. Corroborating 
such an action, vitamin D deficiency has been suggested to contribute to the 
advent of sarcopenia in rodent muscles via diminished muscle stem cell 
proliferative and skeletal muscle regenerative potential by down-regulation of the 
Notch signalling pathway (Domingues-Faria et al., 2014). Notably, increased 
fibre size and strength has been reported in rat muscles electroporated with the 
vitamin D receptor (Bass et al., 2020). These effects were attributed partly to an 
increase in muscle stem cell activity. 
Collectively, our results suggest that vitamin D plays a role in muscle stem 
cell self-renewal and quiescence, possibly by modulating the FOXO3 and Notch 
signalling pathways. This could be of importance for the overall functionality of 
the skeletal muscle tissue, especially in the ageing individual. The levels of the 
biologically active form of vitamin D is strictly regulated and well maintained 
despite very low levels of the prohormone 25(OH)D (Need et al., 2008). 
Impaired skeletal muscle function due to vitamin D deficiency is therefore 
likely uncommon. However, this will be of importance in conditions associated 
with a decline in the synthesis of the biologically active form of vitamin D, such 
as in chronic kidney disease, or in severe vitamin D deficiency.  
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Cellular mechanisms of fatigue in human muscle fibres 
Study III highlighted that impaired SR Ca2+ release has a prominent role in the 
force loss during fatigue and in the early recovery period in human muscle fibres. 
This was in line with previous papers identifying reduced SR Ca2+ release as an 
important underlying cause of muscle fatigue in rodent fibres (Westerblad & 
Allen, 1991, 1993a). Impaired SR Ca2+ release is believed to stem from Ca2+-Pi 
precipitation in the SR (Fryer et al., 1995; Westerblad & Allen, 1996), in 
combination with an inhibition of the RyR1 channel caused by the depletion of 
cytosolic [ATP] and accumulation of free [Mg2+] (Blazev & Lamb, 1999). 
A distinct initial phase of increased tetanic [Ca2+]i while tetanic force declines, 
previously described in rodent fibres, was observed in human fatigue-sensitive 
fibres. This early force reduction has been attributed primarily to accumulation of 
Pi that depresses maximal Ca2+-activated force (Pate & Cooke, 1989; Millar & 
Homsher, 1990; Dahlstedt et al., 2000). Considering the identical pattern seen in 
fatigue-sensitive human fibres, we suggest this to be the most likely cause also in 
human fibres.  
Unlike in rodent fibres, a reduction in myofibrillar Ca2+ sensitivity did not 
contribute to fatigue in human muscle fibres. Intriguingly, an increase in 
myofibrillar Ca2+ sensitivity was seen in fatigue-resistant fibres. This implies that 
changes in myofibrillar Ca2+ sensitivity can contribute to the fatigue-resistance of 
slow-twitch human fibres. The underlying mechanisms of fatigue between human 
and rodent muscle fibres are illustrated in Figure 8.1. 
 
Figure 8.1. Illustration of the cellular mechanisms of fatigue in rodent and human 
muscle fibres. Contribution of changes in maximal Ca2+-activated force, reduced SR Ca2+ 
release, and decreased myofibrillar Ca2+ sensitivity to fatigue in rodent (A) and human (B) 
fast-twitch fibres. Note that in rodent fibres (A) both a reduced SR Ca2+ release and 
decreased myofibrillar Ca2+ sensitivity contributes to the accelerated final decline in force, 
while in human fibres (B) this is caused exclusively by an impaired SR Ca2+ release. 
Force-[Ca2+]i relation in unfatigued (solid line) and fatigued (dashed line) fibres. 
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Fatigue-induced changes in myofibrillar Ca2+ sensitivity have been 
investigated in human skinned fibres subjected to prior fatiguing stimulation in 
vivo. Results from these studies suggest that contractile-induced changes are 
multifaceted and can induce both an increased and decreased myofibrillar Ca2+ 
sensitivity of slow- and fast-twitch fibres (Hvid et al., 2013; Gejl et al., 2016; 
Lamboley et al., 2020). Contractile-induced RONS is one tentative factor 
involved in the modulation of myofibrillar Ca2+ sensitivity. Notably, RONS-
mediated modifications of the fast troponin I isoform have been linked to both 
and increase and a decrease in myofibrillar Ca2+ sensitivity (Murphy et al., 2008; 
Mollica et al., 2012; Dutka et al., 2017). This was explained by a competitive 
action on the Cys134 residue of troponin I by different RONS-species, which 
could explain the reported diversity of changes in myofibrillar Ca2+ sensitivity. 
Additionally, phosphorylation of the regulatory myosin light chain of fast-twitch 
fibres has been acknowledged to increase myofibrillar Ca2+ sensitivity (Sweeney 
et al., 1993). An alternative hypothesis is that ADP and AMP accumulates in 
human fatigue-resistant fibres, due to the lower AMP deaminase and adenylate 
kinase activity in slow-twitch than in fast-twitch fibres (Borges & Essén-
Gustavsson, 1989; Norman et al., 1994). Notably, ADP has been shown to 
increase the myofibrillar Ca2+ sensitivity of slow-twitch fibres (Macdonald & 
Stephenson, 2006).   
Acidosis and human muscle fatigue 
Coherent with findings in rodents, intracellular acidosis caused a decrease in 
myofibrillar Ca2+ sensitivity while tetanic [Ca2+]i increased in unfatigued human 
fibres. These changes inferred under acidic conditions in unfatigued fibres are 
strikingly different to the fatigue-induced changes under control conditions. This 
indicates that intracellular acidosis does not occur during fatigue under the present 
conditions or, alternatively, that other contractile-induced changes completely 
offset the effects of acidosis. Owing to a lack of tissue, fatigue-induced changes in 
pHi were not measured in any of the human fibres. Therefore, we cannot exclude 
the possibility that fatigue under the current experimental conditions results in a 
less marked drop in pHi than what is seen in vivo. Notably, in rodent fibres 
fatigued by similar experimental protocols as in the present study, development of 
intracellular acidosis of a magnitude similar to that in human muscles fatigued in 
vivo has been reported (Sahlin et al., 1975; Sahlin et al., 1976; Bruton et al., 
1998). Major differences in fatigue-induced changes in pHi between the current 
experimental setting and the in vivo situation thus appear unlikely. To fully 
address these questions, future studies should include measurements of fatigue-
induced changes in pHi and [Ca2+]i under control and acidic conditions, 
respectively.  
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In order to maintain tetanic force following a decrease in myofibrillar Ca2+ 
sensitivity, tetanic [Ca2+]i must be adjusted accordingly. This will infer an 
increased energetic cost of force production due to the demand for energy-
dependent removal of Ca2+ during relaxation. In analogy, fatigue is mitigated 
when myofibrillar Ca2+ sensitivity is increased (Cheng et al., 2019). It thus 
appears likely that acidosis would exacerbate fatigue by increasing the metabolic 
cost of force production. This may become evident when combined with other 
mechanisms affecting force production, as previously demonstrated under 
circumstances of severe acidosis combined with markedly elevated Pi 
concentrations (Cooke et al., 1988; Nelson et al., 2014; Nelson & Fitts, 2014; 
Sundberg et al., 2018). Repeated sprints may be such an example where severe 
acidosis is combined with profound changes in metabolites to further aggravate 
fatigue (Figure 8.2).  
 
 
Figure 8.2. Tentative effects of acidosis on human muscle fatigue tolerance. A, the 
myofibrillar Ca2+ sensitivity is reduced under acidic conditions, but this effect is offset by 
an increase in tetanic [Ca2+]i in unfatigued human muscle fibres. B and C, illustration of 
the hypothetic response to repeated fatigue bouts in human muscle fibres under non-acidic 
(B) and acidic conditions (C).  
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The role of sphingomyelinase in disease-related loss of 
muscle function and mass 
Study IV implicate elevated sphingomyelinase activity as an underlying cause of 
disease-related loss of muscle function and mass. The following findings support 
this notion: (i) sphingomyelinase decreased myofibrillar Ca2+ sensitivity and 
impaired SR Ca2+ release to depress force in intact muscle fibres, (ii) 
transcriptional changes promoting muscle atrophy processes were induced upon 
sphingomyelinase exposure in human fibres, (iii) the activity of intramuscular 
sphingomyelinase was elevated in heart failure compared to control individuals 
and (iv) positively correlated with circulating markers of inflammation, atrophy 
and factors carrying prognostic value in heart failure.  
The effects of sphingomyelinase on force generation and myofibrillar Ca2+ 
sensitivity are in line with previous reports in rodent fibres (Ferreira et al., 2012; 
Empinado et al., 2014; Loehr et al., 2014; Bost et al., 2015). We report the first 
study of the effects of sphingomyelinase on SR Ca2+ release. Previous studies 
have been limited to chemically skinned fibres and muscle bundles, which do not 
allow such investigations (Place et al., 2010; Cheng & Westerblad, 2017). By 
demonstrating a depressive effect of sphingomyelinase on SR Ca2+ release, our 
data thus add novel insight into the force depression caused by sphingomyelinase.  
In daily life, the ability to endure a physical activity at a set intensity or load 
over time (i.e. fatigue resistance) is dictated by the muscle strength and 
endurance. With all other variables set, if muscle strength declines this will 
demand that each contraction requires a higher α-motoneuron firing frequency in 
order to elevate [Ca2+]i and to produce the required force. This will increase the 
energetic cost of each contraction and inevitably shorten the time to task failure, 
i.e. exhaustion. The muscle weakness caused by sphingomyelinase will thus be 
experienced as a decreased fatigue resistance in afflicted patients (Figure 8.3). In 
severe cases, the demands of daily life activities (e.g. rising up from a chair, 
walking up stairs) will demand near maximal Ca2+-activated contractions and will 
be perceived as profound and debilitating muscle weakness and fatigue 
intolerance. 
In human muscle fibres, transcriptional changes induced by sphingomyelinase 
included an up-regulation of genes involved in proteasome degradation and a 
down-regulation of genes encoding ribosomal proteins. The ubiquitin-proteasome 
is one of the two major proteolytic systems reported to be involved in muscle 
atrophy (Bonaldo & Sandri, 2013). Gene expression analyses of diverse clinical 
conditions associated with muscle atrophy have revealed common transcriptional 
changes of genes regulating the ubiquitin-proteasome system (Bodine et al., 2001; 
Gomes et al., 2001). These include an up-regulation of transcripts encoding 
ubiquitin, ubiquitin-conjugating enzymes, ubiquitin-protein ligases and several 
proteasome subunits (Lecker et al., 2004). Notably, several of these common 
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transcripts, including essential subunits of the 20s core and 19s regulatory 
proteasome components, as well as polyubiquitin C, were induced in human 
muscle fibres exposed to sphingomyelinase. Among the ribosomal proteins 
transcriptionally repressed following sphingomyelinase exposure were RPL6, a 
component of the 60s ribosomal subunit also known to be an intracellular partner 
of FGF2 (Shen et al., 1998). RPL6-FGF2 interaction is thought to promote cell 
survival (Sluzalska et al., 2020) and thus supressed RPL6 transcription may 
promote atrophy via cellular apoptosis. In light of the reported association of 
sphingomyelinase activity and muscle atrophy, e.g., in heart failure patients 
(Doehner et al., 2007), and our finding of elevated sphingomyelinase activity in 
skeletal muscle of heart failure patients, a decisive role of sphingomyelinase in 
disease-related muscle atrophy is suggested.  
In skeletal muscle, TNFα acts through TNF-RI to activate neutral 
sphingomyelinase-3 (Moylan et al., 2014).  Neutral sphingomyelinase-3 does not 
have a well-defined role in other organs and does not appear to be critical for 
general sphingolipid metabolism. Hence, it provides a tentative target for 
selective inhibition that could mitigate disease-related muscle dysfunction and 
muscle wasting. Given the emerging role of sphingomyelinase activation in 
various clinical conditions, and the recent introduction of inhibitors of other 
sphingomyelinase isoforms (Sala et al., 2020), this will be an interesting area of 
research to follow in the future. 
 
Figure 8.3. Illustration of the effects of sphingomyelinase on human muscle force 
production, tetanic [Ca2+]i, and plausible effects on fatigue tolerance. A, 
sphingomyelinase depresses force by reducing tetanic [Ca2+]i and decreasing myofibrillar 
Ca2+ sensitivity. B, plausible effects of intracellular sphingomyelinase on the fatigue 
tolerance of human muscle fibres. A and B, sphingomyelinase reduces myofibrillar Ca2+ 
sensitivity so that larger increases in [Ca2+]i are needed to attain maximal Ca2+-activated 
force (i), while equimolar [Ca2+]i produces less force than in controls (ii). The combined 
effects of reduced myofibrillar Ca2+ sensitivity and impaired SR Ca2+ release severely 
depresses force in fibres exposed to sphingomyelinase (iii). 
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